These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32001171)

  • 21. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.
    Ebenau JL; Timmers T; Wesselman LMP; Verberk IMW; Verfaillie SCJ; Slot RER; van Harten AC; Teunissen CE; Barkhof F; van den Bosch KA; van Leeuwenstijn M; Tomassen J; Braber AD; Visser PJ; Prins ND; Sikkes SAM; Scheltens P; van Berckel BNM; van der Flier WM
    Neurology; 2020 Jul; 95(1):e46-e58. PubMed ID: 32522798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From Subjective Cognitive Decline to Alzheimer's Disease: The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-Year Follow-Up Study.
    Bessi V; Mazzeo S; Padiglioni S; Piccini C; Nacmias B; Sorbi S; Bracco L
    J Alzheimers Dis; 2018; 63(4):1523-1535. PubMed ID: 29782316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.
    Wang X; Freiesleben SD; Schneider LS; Preis L; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Hansen N; Jessen F; Rostamzadeh A; Duzel E; Glanz W; Incesoy EI; Buerger K; Janowitz D; Ewers M; Perneczky R; Rauchmann BS; Teipel SJ; Kilimann I; Goerss D; Laske C; Munk MHJ; Spottke A; Roy-Kluth N; Heneka MT; Brosseron F; Wagner M; Wolfsgruber S; Ramirez A; Kleineidam L; Stark M; Peters O
    Neurology; 2024 Oct; 103(8):e209806. PubMed ID: 39303184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of stable and unstable patterns of subjective cognitive decline - results from the Leipzig Longitudinal Study of the Aged (LEILA75+).
    Roehr S; Villringer A; Angermeyer MC; Luck T; Riedel-Heller SG
    BMC Geriatr; 2016 Nov; 16(1):180. PubMed ID: 27814674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subjective Cognitive Decline: Level of Risk for Future Dementia and Mild Cognitive Impairment, a Meta-Analysis of Longitudinal Studies.
    Pike KE; Cavuoto MG; Li L; Wright BJ; Kinsella GJ
    Neuropsychol Rev; 2022 Dec; 32(4):703-735. PubMed ID: 34748154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A; Balasa M; Olives J; Antonell A; Iranzo A; Castellví M; Bosch B; Grau-Rivera O; Fernandez-Villullas G; Rami L; Lladó A; Sánchez-Valle R; Molinuevo JL
    Neurodegener Dis; 2016; 16(1-2):69-76. PubMed ID: 26560503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD.
    Chipi E; Bellomo G; Salvadori N; Montanucci C; Gaetani L; Paolini Paoletti F; Parnetti L
    J Prev Alzheimers Dis; 2023; 10(3):523-529. PubMed ID: 37357293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Erlangen Score Algorithm in the diagnosis and prediction of the progression from subjective cognitive decline and mild cognitive impairment to Alzheimer-type dementia.
    Filipek-Gliszczyńska A; Barczak A; Budziszewska M; Mandecka M; Gabryelewicz T; Barcikowska M
    Folia Neuropathol; 2018; 56(2):88-96. PubMed ID: 30509028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort.
    Kleipool EEF; Trappenburg MC; Rhodius-Meester HFM; Lemstra AW; van der Flier WM; Peters MJL; Muller M
    J Alzheimers Dis; 2019; 71(1):317-325. PubMed ID: 31381517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subjective cognitive decline and progression to dementia in Parkinson's disease: a long-term follow-up study.
    Galtier I; Nieto A; Lorenzo JN; Barroso J
    J Neurol; 2019 Mar; 266(3):745-754. PubMed ID: 30635723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment.
    Fernández-Blázquez MA; Ávila-Villanueva M; Maestú F; Medina M
    J Alzheimers Dis; 2016 Mar; 52(1):271-81. PubMed ID: 27060949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrinsic functional connectivity, CSF biomarker profiles and their relation to cognitive function in mild cognitive impairment.
    Matura S; Köhler J; Reif A; Fusser F; Karakaya T; Scheibe M; Ehret F; Hartmann D; Kang JS; Mayer C; Prvulovic D; Pantel J
    Acta Neuropsychiatr; 2020 Aug; 32(4):206-213. PubMed ID: 31801648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia.
    Liew TM
    Alzheimers Res Ther; 2020 Oct; 12(1):135. PubMed ID: 33109275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.